These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28035396)

  • 1. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.
    Lee YJ; Lim T; Han MS; Lee SH; Baek SH; Nan HY; Lee C
    Oncol Rep; 2017 Feb; 37(2):1219-1226. PubMed ID: 28035396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells.
    Kim KC; Baek SH; Lee C
    Int J Oncol; 2015 Dec; 47(6):2296-303. PubMed ID: 26498137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mistletoe (Viscum album) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells.
    Kim S; Kim KC; Lee C
    Phytomedicine; 2017 Dec; 36():183-193. PubMed ID: 29157814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells.
    Kim NY; Suh YA; Kim S; Lee C
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32219334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
    Kim NY; Lee HY; Lee C
    Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axl receptor tyrosine kinase is a novel target of apigenin for the inhibition of cell proliferation.
    Kim KC; Choi EH; Lee C
    Int J Mol Med; 2014 Aug; 34(2):592-8. PubMed ID: 24926787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
    Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
    Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells.
    Al Kafri N; Hafizi S
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
    Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
    Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
    Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV
    PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
    Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
    Tsou WI; Nguyen KQ; Calarese DA; Garforth SJ; Antes AL; Smirnov SV; Almo SC; Birge RB; Kotenko SV
    J Biol Chem; 2014 Sep; 289(37):25750-63. PubMed ID: 25074926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carvacrol Targets AXL to Inhibit Cell Proliferation and Migration in Non-small Cell Lung Cancer Cells.
    Jung CY; Kim SY; Lee C
    Anticancer Res; 2018 Jan; 38(1):279-286. PubMed ID: 29277784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells.
    Lee YJ; Kim SY; Lee C
    Mol Med Rep; 2019 Apr; 19(4):3230-3236. PubMed ID: 30816529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
    Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
    Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.
    Huang KY; Wang TH; Chen CC; Leu YL; Li HJ; Jhong CL; Chen CY
    Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL.
    Iida K; Sakai R; Yokoyama S; Kobayashi N; Togo S; Yoshikawa HY; Rawangkan A; Namiki K; Suganuma M
    Sci Rep; 2017 Dec; 7(1):17770. PubMed ID: 29259259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
    Bae SY; Hong JY; Lee HJ; Park HJ; Lee SK
    Oncotarget; 2015 Apr; 6(12):10146-60. PubMed ID: 25760142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.
    Suh YA; Jo SY; Lee HY; Lee C
    Int J Oncol; 2015 Mar; 46(3):1405-11. PubMed ID: 25544427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.